Achilles Therapeutics Plc - ADR

NASDAQ:ACHL   4:00:00 PM EDT
2.02
+0.12 (+6.32%)
5:31:42 PM EDT: $2.02 0.00 (0.00%)
Earnings Announcements

Achilles Therapeutics Reports Third Quarter Financial Results

Published: 11/08/2022 12:43 GMT
Achilles Therapeutics Plc - ADR (ACHL) - Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights.
Strong Cash Balance of $179.9 Million Supports All Planned Operations Into Q2 2025.
Qtrly Loss per Share $0.32.
Q3 Earnings per Share View $-0.55 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.45

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.51

More details on our Analysts Page.